Lactate dehydrogenase A

Lactate dehydrogenase A
Name	Lactate dehydrogenase A
Ec number	1.1.1.27
Cas number	9001-60-9
Gene	LDHA
Organism	Homo sapiens

Lactate dehydrogenase A is a NAD-dependent oxidoreductase that catalyzes the interconversion of pyruvate and L-lactate, coupling glycolysis to anaerobic metabolism. First characterized in studies alongside enzymes from Krebs investigators and early biochemists such as Otto Warburg and Arthur Harden, the enzyme has become central to research in cancer metabolism, hypoxia responses, and exercise physiology. LDHA is encoded by the human LDHA gene on chromosome 11 and forms homotetramers predominantly expressed in skeletal muscle and fast-twitch fibers studied by groups at institutions like Harvard University, Cold Spring Harbor Laboratory, and Max Planck Society.

Structure and Catalytic Mechanism

The LDHA polypeptide adopts the canonical Rossmann-fold architecture described in structural studies by laboratories at European Molecular Biology Laboratory, with a conserved NAD-binding motif observed in crystal structures deposited by consortia from Brookhaven National Laboratory and Protein Data Bank. X-ray crystallography and cryo-EM analyses led by teams at Stanford University and European Synchrotron Radiation Facility reveal an active site defined by residues that stabilize the pyruvate substrate and the catalytic His-Arg-Asp triad analogous to mechanisms proposed by researchers at Max Planck Institute for Biophysical Chemistry. The enzyme functions as a tetramer; quaternary assembly principles echo oligomerization patterns reported for enzymes from Escherichia coli and Saccharomyces cerevisiae. Catalysis proceeds via hydride transfer from NADH to the carbonyl of pyruvate, a mechanism elaborated in reviews from Nature Reviews Molecular Cell Biology and mechanistic studies at University of Cambridge and Massachusetts Institute of Technology.

Genetics and Expression

Human LDHA is located on chromosome 11 and was mapped using techniques developed at National Institutes of Health and described in genetic catalogs maintained by Ensembl and GenBank. Expression profiling across tissues by consortia such as the Human Protein Atlas and the GTEx project shows high LDHA mRNA and protein levels in skeletal muscle, heart, and certain hematopoietic lineages, with developmental regulation documented in studies from University of Oxford and Johns Hopkins University. Transcriptional control involves promoters responsive to transcription factors characterized at Cold Spring Harbor Laboratory and EMBL-EBI, including binding sites for Hypoxia-inducible factor 1 (HIF-1) described in seminal work from groups at Massachusetts General Hospital and Karolinska Institutet. Comparative genomics studies by teams at Broad Institute highlight conserved LDHA orthologs across metazoans such as Drosophila melanogaster and Caenorhabditis elegans.

Biological Function and Metabolic Role

LDHA catalyzes the terminal step of anaerobic glycolysis, regenerating NAD+ to sustain ATP production under low-oxygen conditions studied in contexts from Mount Everest physiology to ischemia models at Mayo Clinic. Its role in the Warburg effect was elaborated by researchers at Institute of Cancer Research and labs at University College London, linking LDHA activity to proliferative phenotypes in tumor models investigated at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. LDHA participates in metabolic shuttles across cellular compartments, interacting functionally with enzymes of the tricarboxylic acid cycle and mitochondrial pathways characterized at Salk Institute and University of California, San Diego. In muscle physiology, LDHA contributes to lactate production during exercise protocols developed by teams at Stanford University and University of Melbourne and to inter-organ lactate exchange described in studies from Imperial College London.

Regulation and Post-translational Modifications

LDHA expression and activity are regulated at multiple levels by signaling pathways investigated at Cold Spring Harbor Laboratory and Scripps Research, including transcriptional upregulation by HIF-1 under hypoxia and modulation by oncogenic drivers such as MYC and PI3K characterized by groups at Whitehead Institute and Memorial Sloan Kettering Cancer Center. Post-translational modifications including phosphorylation, acetylation, and ubiquitination have been reported in proteomic surveys from European Proteomics Association and mass-spectrometry platforms at EMBL; specific phosphorylation events altering catalytic efficiency were studied by laboratories at University of Pennsylvania and Yale University. Proteostasis and degradation pathways involving the ubiquitin–proteasome system and chaperones described at Rockefeller University influence LDHA stability during stress responses investigated at NIH.

Clinical Significance and Disease Associations

Elevated LDHA activity and serum lactate dehydrogenase levels are biomarkers in oncology cohorts at MD Anderson Cancer Center and Cleveland Clinic and correlate with prognosis in malignancies such as non-small-cell lung carcinoma, lymphoma, and pancreatic cancer examined in clinical trials at Johns Hopkins Medicine and Mayo Clinic. Mutations and altered expression of LDHA have been implicated in rare metabolic disorders profiled by American College of Medical Genetics and in muscle myopathies studied at Boston Children's Hospital. In infectious disease and sepsis research at Centers for Disease Control and Prevention and World Health Organization, LDH levels serve as indicators of tissue damage. LDHA involvement in cardiovascular ischemia and stroke pathophysiology has been characterized in translational studies at Cleveland Clinic and Massachusetts General Hospital.

Therapeutic Targeting and Inhibitors

LDHA has been pursued as a therapeutic target in oncology and metabolic disease by pharmaceutical programs at Pfizer, Novartis, and biotechnology firms emerging from Cambridge, Massachusetts and Silicon Valley. Small-molecule inhibitors such as oxamate analogs and novel scaffolds discovered in high-throughput screens at GlaxoSmithKline and academic centers including University of Toronto show proof-of-concept efficacy in preclinical models from Dana-Farber Cancer Institute and Sloan Kettering. Combination strategies pairing LDHA inhibition with immune checkpoint blockade studied at Memorial Sloan Kettering Cancer Center and UCSF are in early-phase trials coordinated with cooperative groups like NCI and European Society for Medical Oncology. Challenges documented by regulatory agencies such as FDA highlight the need to balance target engagement with effects on normal tissues, and drug development efforts continue in collaboration with consortia at Wellcome Trust and industrial partners.

Category:Human enzymes